z-logo
open-access-imgOpen Access
Francisella tularensis - Immune Cell Activator, Suppressor, or Stealthy Evader: The Evolving View from the Petri Dish
Author(s) -
Kristen M. Holland,
Sarah Rosa,
Karsten R. O. Hazlett
Publication year - 2016
Publication title -
journal of bioterrorism and biodefense
Language(s) - English
Resource type - Journals
ISSN - 2157-2526
DOI - 10.4172/2157-2526.1000144
Subject(s) - francisella tularensis , tularemia , francisella , biology , microbiology and biotechnology , immune system , bacteria , immunology , virulence , gene , genetics
One of the hallmarks of pulmonary tularemia, which results from inhalation of Francisella tularensis - a significant bioterrorism concern, is the lack of an acute T H 1-biased inflammatory response in the early phase of disease (days 1-3) despite significant bacterial loads. In an effort to understand this apparent hypo-responsiveness, many laboratories have utilized in vitro cell-based models as tools to probe the nature and consequences of host cell interactions with F. tularensis . The first uses of this model suggested that mammalian host cells recognize this bacterium principally through TLR2 to evoke a robust, classical T H 1-biased cytokine response including TNF, IL-6, IL-1β, and IFN-γ. Others used this model in concert with a variety of non-genetic perturbations of the bacterial-host cell interaction and suggested that F. tularensis actively-suppressed the cellular response. Consistent with this notion, others engaged this model to assess isogenic mutants and, in many cases, found the mutant bacteria to be more pro-inflammatory than their WT counter-parts. Frequently, these observations were interpreted as evidence for the immunosuppressive function of the gene of interest. However, recently appreciated roles of the health of the bacterium and the impact of host factors have refined this model to suggest a "stealthy" mode of bacterial-host cell interaction (rather than one involving active suppression) consistent with the observations during early phase disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here